Article Proteomic Analysis of Urinary Microvesicles and Exosomes In

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Article Proteomic Analysis of Urinary Microvesicles and Exosomes in Medullary Sponge Kidney Disease and Autosomal Dominant Polycystic Kidney Disease Maurizio Bruschi,1 Simona Granata,2 Laura Santucci,1 Giovanni Candiano,1 Antonia Fabris,2 Nadia Antonucci,2 Andrea Petretto,3 Martina Bartolucci,3 Genny Del Zotto ,4 Francesca Antonini,4 Gian Marco Ghiggeri ,5 Antonio Lupo,2 Giovanni Gambaro,6 and Gianluigi Zaza 2 1Division of Nephrology, Dialysis, Abstract and Transplantation, Background and objectives Microvesicles and exosomes are involved in the pathogenesis of autosomal dominant Laboratory of polycystic kidney disease. However, it is unclear whether they also contribute to medullary sponge kidney, a Molecular sporadic kidney malformation featuring cysts, nephrocalcinosis, and recurrent kidney stones. We addressed this Nephrology, 3Laboratory of Mass knowledge gap by comparative proteomic analysis. Spectrometry—Core Facilities, Design, setting, participants, & measurements The protein content of microvesicles and exosomes isolated from 4Department of the urine of 15 patients with medullary sponge kidney and 15 patients with autosomal dominant polycystic kidney Research and Diagnostics, and disease was determined by mass spectrometryfollowedby weightedgenecoexpression network analysis,support 5 fi Division of vector machine learning, and partial least squares discriminant analysis to compare the pro les and select the Nephrology, Dialysis most discriminative proteins. The proteomic data were verified by ELISA. and Transplantation, Istituto di Ricovero e Results A total of 2950 proteins were isolated from microvesicles and exosomes, including 1579 (54%) identified in Cura a Carattere fi Scientifico, Istituto all samples but only 178 (6%) and 88 (3%) speci c for medullary sponge kidney microvesicles and exosomes, and Giannina Gaslini, 183 (6%) and 98 (3%) specific for autosomal dominant polycystic kidney disease microvesicles and exosomes, Genoa, Italy; 2Renal respectively. The weighted gene coexpression network analysis revealed ten modules comprising proteins with Unit, Department of similar expression profiles. Support vector machine learning and partial least squares discriminant analysis Medicine, University identified 34 proteins that were highly discriminative between the diseases. Among these, CD133 was upregulated HospitalofVerona, Verona, Italy; and in exosomes from autosomal dominant polycystic kidney disease and validated by ELISA. 6Division of Nephrology and Conclusions Our data indicate a different proteomic profile of urinary microvesicles and exosomes in patients Dialysis, School of with medullary sponge kidney compared with patients with autosomal dominant polycystic kidney disease. The Medicine, Columbus- fi Gemelli University urine proteomic pro le of patients with autosomal dominant polycystic kidney disease was enriched of proteins Hospital Catholic involved in cell proliferation and matrix remodeling. Instead, proteins identified in patients with medullary University, Rome, Italy sponge kidney were associated with parenchymal calcium deposition/nephrolithiasis and systemic metabolic derangements associated with stones formation and bone mineralization defects. Correspondence: Prof. CJASN 14: 834–843, 2019. doi: https://doi.org/10.2215/CJN.12191018 Gianluigi Zaza, Renal Unit, Department of Medicine, University HospitalofVerona, Introduction The hypothesis that extracellular vesicles are present Piazzale A Stefani 1, fi 37126 Verona, Italy. Extracellular vesicles, such as microvesicles (diameter in human urine (8) was con rmed by the proteomic Email: gianluigi. of 100–1000 nm) and exosomes (diameter of 30–100 identification of membrane proteins in a pellet isolated [email protected] nm), are membrane-enclosed particles released by by the ultracentrifugation of urine samples (9). Such most cells under normal and pathologic conditions urinary extracellular vesicles contain cell-specific (1–5). Microvesicles are shed directly from the plasma marker proteins from every segment of the nephron membrane, whereas exosomes are formed by the (9,10), and they offer a source of potentially valuable fusion of intracellular multivesicular bodies (also urinary biomarkers (10). The intrinsic characteristics of known as late endosomes) with the plasma membrane, extracellular vesicles also suggest that they may play leading to the release of their vesicular contents into an important role in kidney development and kidney the extracellular space. These vesicles can mobilize a disease. Accordingly, extracellular vesicles seem to be large number of biologic factors, including receptors, involved in the mechanism of cystogenesis in autoso- other proteins, nucleic acids, and lipids, thus shuttling mal polycystic kidney disease, a common hereditary information to other cells (6). The transfer of RNA and kidney disorder with a prevalence of 0.1%–0.25%. miRNA can reprogram recipient cells and modify their Autosomal polycystic kidney disease gives rise to phenotype (7). predominantly kidney symptoms, including cysts that 834 Copyright © 2019 by the American Society of Nephrology www.cjasn.org Vol 14 June, 2019 CJASN 14: 834–843, June, 2019 Urinary Proteome Analysis Differentiated MSK versus ADPKD, Bruschi et al. 835 progressively disrupt the kidney parenchyma, leading to autosomal dominant polycystic kidney disease was de- interstitial fibrosis, cellular infiltration, and the loss of pendent on the revised Ravine criteria (20). The study functional nephrons. was carried out in accordance with the Declaration of The proteomic analysis of urinary exosome-like vesicles Helsinki and approved by the institutional ethical board (particularly those containing polycystin) revealed ap- of the University Hospital of Verona (Verona, Italy; proximately 500 autosomal dominant polycystic kidney code 1312CESC) and the Independent Ethics Committee disease–associated proteins, many with signaling func- (Comitato Etico Regione Liguria) on October 14, 2014 tions (11). Furthermore, the quantitative proteomic analysis (study number 408REG2014). of urinary extracellular vesicles from patients affected by a complete spectrum of chronic kidney functional damage Isolation of Microvesicles and Exosomes highlighted 30 proteins strongly associated with the autoso- Second morning urine samples were obtained from mal dominant polycystic kidney disease phenotype, includ- patients and healthy donors. Extracellular vesicles were ing periplakin, envoplakin, villin-1, and complement C3 (12). isolated by centrifugation. Briefly, aliquots of 16 ml were In contrast to the wealth of information available for centrifuged at 16,0003g for 30 minutes at 16°C to remove autosomal dominant polycystic kidney disease, little is cells, debris, and organelles, such as mitochondria. To known about the role of extracellular vesicles in the onset obtain the microvesicle fraction, the supernatant was of medullary sponge kidney, a sporadic cystic kidney centrifuged at 22,0003g for 120 minutes at 16°C (21). The malformation that involves nephrocalcinosis and recurrent microvesicle pellet was rinsed in PBS and centrifuged again kidney stones (13). The detailed analysis of extracellular at 22,0003g; this rinse/centrifugation cycle was carried out vesicles could provide insight into the pathogenesis of this five times in total to obtain a clean microvesicle fraction. The rare disease. Despite sporadic genetic associations (14,15) 3g – supernatant was then centrifuged at 100,000 for 120 and the dysregulation of a few biologic factors (16 18), the minutes at 16°C to pellet the exosomes. The pellet was systemic and kidney biologic/cellular network underlying resuspended in 1 ml 0.25 M sucrose, loaded on a 1-ml this disease is poorly characterized, and its relationship with 30% sucrose cushion, and centrifuged at 100,0003g for other cystic diseases is unclear. 120 minutes at 16°C. The pellet was rinsed in PBS and To address this knowledge gap, we carried out a com- centrifuged again at 100,0003g for 10 minutes at 4°C, and prehensive comparative proteomic analysis of urinary this rinse/centrifugation cycle was carried out five times microvesicles and exosomes to identify differences between in total to obtain a clean exosome fraction. For each assay, medullary sponge kidney and autosomal dominant poly- we have performed the same purification procedure. Each cystic kidney disease in terms of the mechanism of cysto- pellet fraction was stored at 280°C until use. The size and genesis and identify putative diagnostic biomarkers that purity of microvesicles and exosomes isolated by ultracen- distinguish these diseases. In fact, at the moment, no trifugation were confirmed by dynamic light scattering, diagnostic biomarkers are available for both diseases. whereas the antigen profile of exosomes and microvesicles Although some urinary biomarkers for autosomal dominant was performed by Western blot as described in Supple- polycystic kidney disease (NGAL, M-CSF, and MCP-1) (19) mental Material. have been proposed, none of them have been used in clinical practice (19). Additionally, most of them are only effective in the advanced stage of the disease. Identification of Mass Spectrometry both diseases at early stages could help clinicians start The samples were processed by the in-StageTip method prevention, diet adjustment, and for selected patients, with two poly(styrene divinylbenzene) reverse phase m pharmacologic treatment. Finally, they could potentiate sulfonate disks (22). Each pellet was solubilized in 25 l diagnostic
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • Supplemental Figure 1. Vimentin

    Supplemental Figure 1. Vimentin

    Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672
  • Conformational Disruption of Pi3kδ Regulation by Immunodeficiency Mutations in PIK3CD and PIK3R1

    Conformational Disruption of Pi3kδ Regulation by Immunodeficiency Mutations in PIK3CD and PIK3R1

    Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1 Gillian L. Dornana, Braden D. Siempelkampa, Meredith L. Jenkinsa, Oscar Vadasb, Carrie L. Lucasc, and John E. Burkea,1 aDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada V8W 2Y2; bDepartment of Pharmaceutical Chemistry, University of Geneva, CH-1211 Geneva 4, Switzerland; and cDepartment of Immunobiology, Yale University, New Haven, CT 06511 Edited by Lewis C. Cantley, Weill Cornell Medical College, New York, NY, and approved January 12, 2017 (received for review November 2, 2016) Activated PI3K Delta Syndrome (APDS) is a primary immunodefi- domain, and a bilobal kinase domain. All p85 regulatory subunits ciency disease caused by activating mutations in either the contain two SH2 domains (nSH2 and cSH2) linked by a coiled-coil leukocyte-restricted p110δ catalytic (PIK3CD) subunit or the ubiq- region referred to as the inter-SH2 domain (iSH2). The class IA uitously expressed p85α regulatory (PIK3R1) subunit of class IA p110 catalytic subunits are differentially inhibited by p85, with phosphoinositide 3-kinases (PI3Ks). There are two classes of APDS: p110α containing inhibitory contacts between the nSH2 domain of α APDS1 that arises from p110δ mutations that are analogous to p85 and the C2, helical, and kinase domains of p110 , as well as α oncogenic mutations found in the broadly expressed p110α sub- between the iSH2 domain of p85 and the C2 domain of p110 (10). Both p110β and p110δ contain an additional regulatory unit and APDS2 that occurs from a splice mutation resulting in – p85α with a central deletion (Δ434–475).
  • ORIGINAL ARTICLE Flow Cytometric Protein Expression Profiling As a Systematic Approach for Developing Disease-Specific Assays

    ORIGINAL ARTICLE Flow Cytometric Protein Expression Profiling As a Systematic Approach for Developing Disease-Specific Assays

    Leukemia (2006) 20, 2102–2110 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens AC Rawstron, R de Tute, AS Jack and P Hillmen Haematological Malignancy Diagnostic Service (HMDS), Leeds Teaching Hospitals, Leeds, UK Depletion of disease below the levels detected by sensitive sustained remissions only occur in patients achieving an MRD- minimal residual disease (MRD) assays is associated with negative complete response.12 Therefore MRD is increasingly prolonged survival in chronic lymphocytic leukaemia (CLL). being used as an end point for therapeutic trials, and several Flow cytometric MRD assays are now sufficiently sensitive and rapid to guide the duration of therapy in CLL, but generally rely studies are now using the assessment of MRD to define the on assessment of CD20 expression, which cannot be accurately duration of therapy. measured during and after therapeutic approaches containing Approaches using allele-specific oligonucleotide polymerase rituximab. The aim of this study was to use analytical software chain reaction (ASO-PCR) to the immunoglobulin gene of the developed for microarray analysis to provide a systematic B-CLL cell are generally accepted to show the highest sensitivity approach for MRD flow assay development. Samples from CLL for MRD detection. However, more recent four-colour ap- patients (n ¼ 49), normal controls (n ¼ 21) and other B-lympho- proaches show sensitivities nearing that of ASO-PCR6,11,13 with proliferative disorders (n ¼ 12) were assessed with a panel of 66 antibodies.
  • Enrichment and Characterization of Two Subgroups of Committed Osteogenic Cells in the Mouse Endosteal Bone Marrow with Expressio

    Enrichment and Characterization of Two Subgroups of Committed Osteogenic Cells in the Mouse Endosteal Bone Marrow with Expressio

    ne Marro Bo w f R o e l s a e n a r Chang CF et al., J Bone Marrow Res 2014, 2:2 r c u h o J Journal of Bone Marrow Research DOI: 10.4172/2329-8820.1000144 ISSN: 2329-8820 Research Article Open Access Enrichment and Characterization of Two Subgroups of Committed Osteogenic Cells in the Mouse Endosteal Bone Marrow with Expression Levels of CD24 Ching-Fang Chang1,2, Ke-Hsun Hsu1,2, Chia-Ning Shen1,2,3, Chung-Leung Li2,3* and Jean Lu1,2** 1Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan 2Genomics Research Center, Academia Sinica, Taipei, Taiwan 3Institute of Bioscience and Biotechnology, College of Life Sciences, National Taiwan Ocean University, Keelung, Taiwan Abstract Primary osteogenic cells have been known to reside within the CD45-CD31-Ter119-Sca-1- cell fraction, particularly in the CD51+ subpopulation. However, detailed determination of the frequency of osteogenic cells within this Sca-1- cell population remains yet to be determined. In addition, it is not clear that other cell surface markers can be used to further sub-fractionate this Sca-1-CD51+ osteogenic cell population and to define their developmental stages. In this report, both Sca-1-CD24med and Sca-1- CD24-/lo cells have been shown to be two small subsets of the Sca-1-CD51+ cell fraction. These two cell fractions show subtle difference in the expression level of osteogenic marker genes such as Osx and Opn, and in vitro proliferate rate. All these observations suggest that they may be at different developmental stages of osteogenesis.
  • Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product Data

    Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product Data

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for KN406551 Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product data: Product Type: Knockout Kits (CRISPR) Symbol: Cadherin 16 Locus ID: 1014 Kit Components: , 10 ug , 10 ug : EF1a-GFP-P2A-Puro Disclaimer: The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process. RefSeq: NM_001204744, NM_001204745, NM_001204746, NM_004062 Summary: This gene is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. Mapped to a previously identified cluster of cadherin genes on chromosome 16q22.1, the gene localizes with superfamily members CDH1, CDH3, CDH5, CDH8 and CDH11. The protein consists of an extracellular domain containing 6 cadherin domains, a transmembrane region and a truncated cytoplasmic domain but lacks the prosequence and tripeptide HAV adhesion recognition sequence typical of most classical cadherins. Expression is exclusively in kidney, where the protein functions as the principal mediator of homotypic cellular recognition, playing a role in the morphogenic direction of tissue development. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2020 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) – KN406551 Product images: This product is to be used for laboratory only.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Supplementary Materials

    Supplementary Materials

    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
  • Supplemental Material Annexin A2-S100A10 Represents the Regulatory Component of Maxi-Cl Channel Dependent on Protein Tyrosine De

    Supplemental Material Annexin A2-S100A10 Represents the Regulatory Component of Maxi-Cl Channel Dependent on Protein Tyrosine De

    Supplemental Material Annexin A2-S100A10 Represents the Regulatory Component of Maxi-Cl Channel Dependent on Protein Tyrosine Dephosphorylation and Intracellular Ca2+ Md. Rafiqul Islama Toshiaki Okadaa Petr G. Merzlyaka,b Abduqodir H. Toychieva,c Yuhko Ando-Akatsukad Ravshan Z. Sabirova,b Yasunobu Okadaa,e aDivision of Cell Signaling, National Institute for Physiological Sciences (NIPS), Okazaki, Japan, bInstitute of Biophysics and Biochemistry, National University of Uzbekistan, Tashkent, Uzbekistan, cDepartment of Biological Sciences, State University of New York College of Optometry, New York, NY, USA, dDepartment of Cell Physiology, Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan, eDepartment of Physiology, Kyoto Prefectural University of Medicine, Kyoto, Japan Supplementary Material Supplementary Fig. 1. Maxi-Cl currents in C127 cells were unaffected by siRNA- mediated silencing of three annexin family member genes, Anxa1, Anxa3 and Anxa11. Effects of knockdown mediated by Anxa1-specific siRNA (A), Anxa3-specific siRNA (B) and Anxa11-specific siRNA (C). Top panels: The effects on expression of ANXA mRNAs in C127 cells treated with non-targeting siRNA (cnt) or Anxa1/3/11-specific siRNA (si) detected by RT-PCR using Gapdh as a control. M: molecular size markers (100-bp ladder). These data represent triplicate experiments. Upper-middle panels: Representative time courses of Maxi-Cl current activation recorded at +25 mV after patch excision from C127 cells transfected with Anxa1/3/11-specific siRNA. Lower-middle panels: Voltage- dependent inactivation pattern of Maxi-Cl currents elicited by applying single voltage step pulses from 0 to 25 and 50 mV. Bottom panels: Summary of the effects of non-targeting siRNA (Control) and Anxa1/3/11-specific siRNA on the mean Maxi-Cl currents recorded at +25 mV.
  • Minnelide Effectively Eliminates CD133+ Side Population in Pancreatic Cancer Alice Nomura1, Olivia Mcginn1, Vikas Dudeja1, Veena Sangwan1, Ashok K

    Minnelide Effectively Eliminates CD133+ Side Population in Pancreatic Cancer Alice Nomura1, Olivia Mcginn1, Vikas Dudeja1, Veena Sangwan1, Ashok K

    Nomura et al. Molecular Cancer (2015) 14:200 DOI 10.1186/s12943-015-0470-6 RESEARCH Open Access Minnelide effectively eliminates CD133+ side population in pancreatic cancer Alice Nomura1, Olivia McGinn1, Vikas Dudeja1, Veena Sangwan1, Ashok K. Saluja1,2 and Sulagna Banerjee1,2* Abstract Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a devastating disease hallmarked by limited patient survival. Resistance to chemotherapy, a major cause of treatment failure in PDAC patients, is often attributed to Cancer Stem Cells (CSCs). Pancreatic CSCs are a small subset of quiescent cells within a tumor represented by surface markers like CD133. These cells are responsible not only for tumor recurrence, but also poor prognosis based on their “stem-like” characteristics. At present, conventional therapy is directed towards rapidly dividing PDAC cells and thus fails to target the CSC population. Methods: MIA PaCa-2, S2-013 and AsPC-1 were treated with 12.5 nM triptolide (12 T cells) for 7 days. The surviving cells were recovered briefly in drug-free growth media and then transferred to Cancer Stem cell Media (CSM). As a control, untreated cells were also transferred to CSM media (CSM). The 12 T and CSM cells were tested for stemness properties using RNA and protein markers. Low numbers of CSM and 12 T cells were implanted subcutaneously in athymic nude mice to study their tumorigenic potential. 12 T and CSM cells were sorted for CD133 expression and assayed for their colony forming ability and sphere forming ability. Invasiveness of 12 T cells, CSM and MIA PaCa-2 were compared using Boyden chamber assays.
  • Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon

    Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon

    Towards the Elucidation of Orphan Lysosomal Transporters Quentin Verdon To cite this version: Quentin Verdon. Towards the Elucidation of Orphan Lysosomal Transporters. Cancer. Université Paris Saclay (COmUE), 2016. English. NNT : 2016SACLS144. tel-01827233 HAL Id: tel-01827233 https://tel.archives-ouvertes.fr/tel-01827233 Submitted on 2 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. NNT : 2016SACLS144 THESE DE DOCTORAT DE L’UNIVERSITE PARIS-SACLAY PREPAREE A L’UNIVERSITE PARIS-SUD ECOLE DOCTORALE N°568 BIOSIGNE | Signalisations et réseaux intégratifs en biologie Spécialité de doctorat : aspects moléculaires et cellulaires de la biologie Par Mr Quentin Verdon Towards the elucidation of orphan lysosomal transporters: several shots on target and one goal Thèse présentée et soutenue à Paris le 29/06/2016 » : Composition du Jury : Mr Le Maire Marc Professeur, Université Paris-Sud Président Mr Birman Serge Directeur de recherche, CNRS Rapporteur Mr Murray James Assistant professor, Trinity college Dublin Rapporteur Mr Goud Bruno Directeur de recherche, CNRS Examinateur Mr Gasnier Bruno Directeur de recherche, CNRS Directeur de thèse Mme Sagné Corinne Chargée de recherche, INSERM Co-directeur de thèse Table of contents Remerciements (acknowledgements) 6 Abbreviations 7 Abstracts 10 Introduction 12 1 Physiology of lysosomes 12 1.1 Discovery and generalities 12 1.2 Degradative function 13 1.3.